Thanks for stopping by

Norway Peptides serves qualified researchers and research institutions for in vitro laboratory study only.

Without that affirmation we're unable to offer access to our catalog. We appreciate your understanding.

If you reached this page in error, refresh to try again.

Norway Peptides
Volume pricing
$200
Save $20
$300
Save $35
$450
Save $60
$600
Save $90
Cart: $0.00 No discount yet Add $200 → $20 off
Retatrutide, Norway Peptides
Metabolic

Retatrutide

Triple GLP-1, GIP, and glucagon receptor agonist

$99.99 10 mg vial
≥98% HPLC Purity Third-Party Tested COA per Batch Cold-Chain Ship

About this compound

Retatrutide is a synthetic 39-amino acid peptide and an investigational triple-receptor agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously, making it one of the most pharmacologically novel research peptides in the metabolic research space.

The addition of glucagon-receptor activity to the dual-incretin mechanism (already represented by compounds such as tirzepatide) is hypothesized in the literature to extend the molecule's effects on hepatic lipid handling and energy expenditure beyond what is observed with GLP-1/GIP co-agonism alone. Retatrutide is being studied in metabolic, adipose, and hepatic research models.

Supplied as a sterile lyophilized powder. Reconstitute with bacteriostatic water for in vitro laboratory use only. Not for human or veterinary administration.

Specifications

Molecular Formula
C₂₅₂H₃₈₂N₅₆O₇₆
Molecular Weight
5302.3 g/mol
CAS Number
2381089-83-2
Receptor Targets
GLP-1R + GIPR + GCGR (triple agonist)
Purity
≥98% (HPLC)
Form
Lyophilized white powder
Storage (unopened)
-20°C, protected from light
Storage (reconstituted)
2-8°C, use within 30 days
Vial Sizes
10 mg

Reconstitution & storage

Add 2 mL of bacteriostatic water to the 10 mg vial for a 5 mg/mL working concentration. Swirl gently. Refrigerate (2-8°C) once reconstituted and use within 30 days.

Selected research references

  • Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526.
  • Coskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metab. 2022;34(9):1234-1247.
  • Rosenstock J et al. "Retatrutide once weekly for type 2 diabetes: a phase 2 trial." Lancet. 2023;402(10401):529-544.

References listed for research-context only. Norway Peptides does not endorse, sponsor, or financially benefit from any cited work. Researchers should consult primary sources directly.